Discovery of Novel Tricyclic Thiazepine Derivatives as Anti-Drug-Resistant Cancer Agents by Combining Diversity-Oriented Synthesis and Converging Screening Approach

Jinbao Xiang, Zhuoqi Zhang, Yan Mu, Xianxiu Xu, Sigen Guo, Yong‐Jin Liu, Daniel P. Russo, Hao Zhu, Bing Yan, Xu BaiACS 2016 · DOI

Abstract

An efficient discovery strategy by combining diversity-oriented synthesis and converging cellular screening is described. By a three-round screening process, we identified novel tricyclic pyrido[2,3-b][1,4]benzothiazepines showing potent inhibitory activity against paclitaxel-resistant cell line H460TaxR (EC50 < 1.0 μM), which exhibits much less toxicity toward normal cells (EC50 > 100 μM against normal human fibroblasts). The most active hits also exhibited drug-like properties suitable for further preclinical research. This redeployment of antidepressing compounds for anticancer applications provides promising future prospects for treating drug-resistant tumors with fewer side effects.
BibTeX
@inproceedings{xiang2016discovery,
  author = {Jinbao Xiang and Zhuoqi Zhang and Yan Mu and Xianxiu Xu and Sigen Guo and Yong‐Jin Liu and Daniel P. Russo and Hao Zhu and Bing Yan and Xu Bai},
  title = {{Discovery of Novel Tricyclic Thiazepine Derivatives as Anti-Drug-Resistant Cancer Agents by Combining Diversity-Oriented Synthesis and Converging Screening Approach}},
  booktitle = {ACS},
  year = {2016},
  doi = {10.1021/acscombsci.6b00010},
}

Loading related content...

Figure